Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472765 | 0.93 | GAA (0.35) | ABL1EPHX2HDAC1HDAC2GAA | |
| SCHEMBL16385025 | 0.88 | CA1 (0.33) | GAARAB9ACA1CA2 | |
| SCHEMBL2518670 | 0.83 | EPHX2 (0.38) | EPHX2HDAC1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL2524299 | 0.81 | MTOR (0.37) | ABL1EPHX2GAAALDH1A1POLB | |
| SCHEMBL472295 | 0.80 | CA1 (0.35) | GAARAB9ACA1CA2 | |
| SCHEMBL472622 | 0.80 | CA1 (0.33) | GAASMN1; SMN2ALDH1A1CA1CA2 | |
| SCHEMBL472683 | 0.80 | CA1 (0.34) | GAASMN1; SMN2POLBCA1CA2 | |
| SCHEMBL472769 | 0.79 | CA1 (0.34) | GAARAB9ACA1CA2 | |
| SCHEMBL16508607 | 0.79 | CA1 (0.34) | GAACA1CA2 | |
| SCHEMBL12613679 | 0.79 | PTGES (0.32) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2865369-B1 | Solid dispersions of isoxazoline compounds | SUMITOMO CHEMICAL CO (JP) | 2023-05-24 | — | — | EP | disclosed |
| US-9371293-B2 | Isoxazoline compound composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150119432-A1 | ISOXAZOLINE COMPOUND COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119432-A1 | ISOXAZOLINE COMPOUND COMPOSITION | CHRNA7, CYP3A7, CYP4X1 | ABL1 1890/4885EPHX2 2260/4885HDAC3 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.